Source comparison
Limitations of This Comparison
Even the well-supported parts of this reference carry limitations that a careful reader should keep in view. Population specificity. Tesamorelin’s strong data come entirely from people with HIV-associated lipodystrophy. Extrapolating those results to other pop
This comparison does not assign a generated winner or score.
- Even the well-supported parts of this reference carry limitations that a careful reader should keep in view.
- Population specificity. Tesamorelin’s strong data come entirely from people with HIV-associated lipodystrophy. Extrapolating those results to other populations is not supported by the trials.
- Age of the sermorelin evidence. Sermorelin’s human record is decades old and pediatric; it predates modern trial standards for the adult uses now marketed.
- Cross-trial inference. Comparing the two relies on separate studies with different designs, endpoints, and eras — a structurally weaker basis than a single controlled comparison.
- Surrogate endpoints. Visceral fat and IGF-1 are meaningful measures, but they are surrogate/intermediate endpoints, not hard clinical outcomes like cardiovascular events.
- Product identity. Research-market peptides are not manufactured to pharmaceutical identity and purity standards, so a vial’s contents cannot be assumed from its label without independent testing.